SCHEMBL6447334

SCHEMBL6447334

OCCC(CO)(CO)SCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
PRMT1 Q99873 1/20 0.43
TDP1 Q9NUW8 1/20 0.40
IDO1 P14902 3/20 0.38
NOS1 P29475 2/20 0.38
NOS3 P29474 1/20 0.38
NOS2 P35228 1/20 0.38
TSHR P16473 2/20 0.38
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
CYP2C19 P33261 1/20 0.35
POLB P06746 2/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
HSD17B10 Q99714 1/20 0.33
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7796812 0.77 CYP2D6 (0.61) CYP1A2CYP3A4CYP2D6PRMT1TDP1
SCHEMBL2655561 0.72 CYP1A2 (0.59) CYP1A2CYP3A4CYP2D6PRMT1TDP1
SCHEMBL6832085 0.72 CYP3A4 (0.46) CYP1A2CYP3A4CYP2D6PRMT1TDP1
SCHEMBL6849329 0.70 CYP1A2 (0.52) CYP1A2CYP3A4CYP2D6PRMT1TDP1
SCHEMBL5680340 0.68 CYP1A2 (0.46) CYP1A2CYP3A4CYP2D6PRMT1TDP1
Ethylene Glycol SCHEMBL28263634 0.68 CYP2C19 (0.54) CYP1A2CYP3A4CYP2D6TDP1IDO1
SCHEMBL31713424 0.66 SLC6A4 (0.45) CYP1A2CYP3A4CYP2D6PRMT1MAOA
SCHEMBL2154643 0.66 CYP1A2 (0.52) CYP1A2CYP3A4CYP2D6PRMT1IDO1
SCHEMBL5680420 0.66 CYP2D6 (0.63) CYP1A2CYP3A4CYP2D6PRMT1IDO1
Bromide SCHEMBL20854775 0.65 CYP1A2 (0.57) CYP1A2CYP3A4CYP2D6PRMT1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1126838-A4 NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2005-02-16 EP disclosed
US-20030207919-A1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use NICOX S.A. (FR) 2003-11-06 US disclosed
US-6593347-B2 Especially a nitrosated and/or nitrosylated arylpropionic acid, arylacetic acid, enolic anilide or an oxicam NITROMED, INC. 2003-07-15 US disclosed
US-20020016322-A1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use NICOX S.A. (FR) 2002-02-07 US disclosed
US-6297260-B1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use NITROMED, INC. 2001-10-02 US disclosed
EP-1126838-A1 NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2001-08-29 EP disclosed
WO-2000025776-A1 NITROSATED AND NITROSYLATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016322-A1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositons and methods of use NOS2, NOS3, NOS1 CYP1A2 136/4885CYP3A4 101/4885CYP2D6 593/4885
US-20030207919-A1 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use NOS2, NOS1, NOS3 CYP1A2 150/4885CYP3A4 201/4885CYP2D6 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.